Form 8-K

8-K — Silexion Therapeutics Corp

Accession: 0001178913-26-003966

Filed: 2026-08-10

Period: 2026-08-10

CIK: 0002022416

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — zk2635901.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (exhibit_99-1.htm)

GRAPHIC (image_001.jpg)

GRAPHIC (image_002.jpg)

GRAPHIC (image_003.jpg)

GRAPHIC (image_004.jpg)

GRAPHIC (image_005.jpg)

GRAPHIC (image_006.jpg)

GRAPHIC (image_007.jpg)

GRAPHIC (image_008.jpg)

GRAPHIC (image_009.jpg)

GRAPHIC (image_010.jpg)

GRAPHIC (image_011.jpg)

GRAPHIC (image_012.jpg)

GRAPHIC (image_013.jpg)

GRAPHIC (image_014.jpg)

GRAPHIC (image_015.jpg)

GRAPHIC (image_016.jpg)

GRAPHIC (image_017.jpg)

GRAPHIC (image_018.jpg)

GRAPHIC (image_019.jpg)

GRAPHIC (image_020.jpg)

GRAPHIC (image_021.jpg)

GRAPHIC (image_022.jpg)

GRAPHIC (image_023.jpg)

GRAPHIC (image_024.jpg)

GRAPHIC (image_025.jpg)

GRAPHIC (image_026.jpg)

GRAPHIC (image_027.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: zk2635901.htm · Sequence: 1

false

0002022416

00-0000000

0002022416

2026-08-10

0002022416

us-gaap:CommonStockMember

2026-08-10

0002022416

SLXN:WarrantsExercisableForOrdinarySharesMember

2026-08-10

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

August 10, 2026

Silexion Therapeutics

Corp

(Exact name of registrant as specified in its charter)

Cayman Islands

001-42253

N/A

(State or other jurisdiction

(Commission File Number)

(I.R.S. Employer

of incorporation)

Identification No.)

12 Abba Hillel Road

Ramat-Gan, Israel

5250606

(Address of principal executive offices)

(Zip Code)

+972-3-756-4999

(Registrant’s telephone number, including

area code)

N/A

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously

satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on

which registered

Ordinary Shares, par value $0.135 per share

SLXN

The Nasdaq Stock Market LLC

Warrants exercisable for Ordinary Shares at an exercise price of $15,525.00 per share

SLXNW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On August 10, 2026, Silexion Therapeutics Corp

(the “Company”) published an updated corporate presentation titled “Silencing Oncogenes at the Level of Gene

Expression” in which the Company included an updated timeline for the expected clinical testing and regulatory approval process

for its SIL 204 lead product candidate. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this

“Form 8-K”) and is incorporated herein by reference.

The information in Item 7.01 of this Form 8-K,

including the presentation furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed “filed” for the purposes

of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore,

the information in Item 7.01 of this Form 8-K, including the presentation, shall not be deemed to be incorporated by reference in the

filings of the registrant under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1

Corporate Presentation titled “Silencing Oncogenes at the Level of Gene Expression” dated August 2026

104

Cover Page Interactive Data File (formatted in Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SILEXION THERAPEUTICS CORP

Date: August 10, 2026

/s/ Ilan Hadar

Name:

Ilan Hadar

Title:

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: exhibit_99-1.htm · Sequence: 2

Exhibit 99.1

Sile ncing Oncogenes at the Level of Gene Expression August 2026 Nasdaq: SLXN

Forward - Looking Statement The statements contained in this presentation that are not purely historical are forward - looking statements . Our forward - looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future . In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward - looking statements . The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward - looking statements, but the absence of these words does not mean that a statement is not forward - looking . Forward - looking statements in this presentation may include, for example, statements about : • the future performance of the Company, including Silexion’s projected timeline for regulatory approvals of its product candidates ; and • the Company’s future plans and opportunities . The forward - looking statements contained in this presentation are based on our current expectations and beliefs concerning future developments and their potential effects on us . There can be no assurance that future developments affecting us will be those that we have anticipated . These forward - looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward - looking statements . These risks and uncertainties include, but are not limited to, the items in the following list : • Silexion is a development - stage company and has a limited operating history on which to assess its business ; • Silexion has never generated any revenue from product sales and may never be profitable ; • The approach Silexion is taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products ; • Silexion does not have experience producing its product candidates at commercial levels, currently has no marketing and sales organization, has an uncertain market receptiveness to its product candidates, and is uncertain as to whether there will be insurance coverage and reimbursement for its potential products ; • Silexion may be unable to attract, develop and/or retain its key personnel or additional employees required for its development and future success ; • Additional factors relating to the business, operations and financial performance of Silexion . Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward - looking statements . We undertake no obligation to update or revise any forward - looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws . 2

Shoot the Messenger Stop Cancer Mutated KRAS Proteins Drive Aggressive Cancers Silexion Develops RNA Silencing Treatments that Abolish KRAS Expression designed to be the most efficacious product for KRAS - driven locally a dvanced Tumors (PDAC, CRC, NSCL ) with meaningful improvement in safety over Pan - RAS inhibitors Currently investigated in Phase 2/3 clinical program initiated July 2026 First generation product showed KRAS silencing potential but highlighted delivery limitation Second generation product (SIL204) designed for enhanced cellular delivery, better stability, and broader antitumor activity Phase 2/3 clinical program initiated, investigating d ual - delivery strategy targeting both primary lesion and metastases PDAC: Pancreatic Ductal Adenocarcinoma; CRC: Colorectal Cancer NSCLC: Non - Small - Cell Lung Cancer

4 1. Lee, J.K. et al. NPJ Precis Oncol. 2022;6(1):91.; 2. Hirshberg Foundation for Pancreatic Cancer Research. Pancreatic canc er Facts. https://pancreatic.org/pancreatic - cancer/pancreatic - cancer - facts. Pancreatic Ductal Adenocarcinoma (PDAC) Colorectal Cancer (CRC) Non - squamous Non - Small - Cell Lung Cancer (Non - sq NSCLC) PDAC: 3 rd leading cause of cancer deaths today in the U.S. 2 , 2 nd leading cause by 2030 2 % KRAS mutations 1 Incidence USA+EU 92% ~200K 49% ~500K 35% ~400K KRAS Mutations are Highly Prevalent Drivers Across Major Solid Tumors High mutation rates spanning cancer types and KRAS variants

G12D G12V G12C G12A G12R Multiple Other KRAS SIL204: Leading siRNA Program with Significant Market Opportunity KRAS mutations are present in ~92% pancreatic cancer cases 1 ROW=rest of the world. *Number of KRAS G12D/V mutated LAPC were calculated based on KRAS mutations being present in 92% of pancreatic cancer patient s, 70 - 75% with KRAS G12D and G12V mutations and 30 - 35% of cases being LAPC. 1. Lee, J.K. et al. NPJ Precis Oncol . 2022;6(1):91. 2. Yousef, A. et al. NPJ Precis Oncol . 2024;8(1):27. 3. Global Cancer Observatory. Pancreatic Cancer. 2022. https://gco.iarc.who.int/media/globocan/factsheets/cancers/13 - pancreas - fact - sheet.pdf. 4. National Cancer Institute. Cancer Sta t Facts: Pancreatic Cancer. 2023. https://seer.cancer.gov/statfacts/html/pancreas.html. SIL204 targets > 74% of KRAS mutations in PDAC 2 Current KRAS G12C therapies address only ~1.5% Total Addressable Market in Localized Advanced Pancreatic Cancer E.U. U.S. 146,477 3 66,400 4 Annual pancreatic cancer cases ~35,000 ~16,000 KRAS - G12D/V mutated LAPC incidence* 5 U.S. ~$2B E.U. ~$3B

BRPC=borderline resectable pancreatic cancer; LAPC = locally advanced pancreatic cancer. Gemenetzis G, et al. Ann Surg . 2019;270(2):340 - 347; Kleeff J, et al. Nat Rev Dis Primers . 2016;2:16022. Local with Micrometastases Metastatic 15 - 25% Resectable + BRPC ~30% LAPC ~50% Metastatic ~75% liver 6 Pancreatic Cancer is Often Systemic Before Visible Metastases Appear Therapy must address undetectable micrometastatic disease as well as the primary tumor

Pancreatic Cancer Remains a High Medical Need Despite RAS Inhibitors 1. National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. https://seer.cancer.gov/statfacts/html/pancreas.html. 2 . Cancers 2021, 13(18), 4724; https://doi.org/10.3390/cancers13184724. 3. Gemenetzis G, et al. Ann Surg . 2019;270(2):340 - 347. 4. Alagesan, B. et al. AARC 2026. 5. Revolution Medicines November 2025 Company Presentation 7 There are no effective treatment options for our targeted indication LAPC • Overall 5 - year survival one of poorest U.S 12.8% 1 , KRAS G12D/V worst survival • Resectable PC - Following surgery with perioperative chemotherapy, ~80% have metastases in 1 yr 2 • Median survival LAPC 14 - 17mo . 3,4 • New small molecule RAS inhibitors efficacy promising and safety acceptable, but large gaps remain before the market is satisfied 5 • Severe or medically significant toxicities that typically requires active medical management and often hospitalization often include: Rash; fatigue; diarrhea; anemia; mucositis; decreased neutrophils

8 Silexion siRNA Silences KRAS at the Source Lead Product: SIL204 F irst - in - class, isoform selective, stable, pan KRAS RNA silencer with delivery system targeting high LDL receptor expressing tumors and micrometastases Targets both active and inactive forms of KRAS Treating closer to the mechanism driving cancer presents a better chance to overcome treatment resistance x Designed to shut down oncogene expression rather than inhibit mutant KRAS protein

SIL204 Targets Both Primary Tumor and Metastases Combined intratumoral and systemic (subcutaneous) dosing controls primary tumor and metastatic spread Primary pancreatic tumor targeted by Intra - tumoral SIL204 Micrometastatic invasions into liver, lung targeted by S yste mic SIL204 Pancreatic cancer often spreads early, before metastases are detectable Systemic SIL204 targets micrometastases Intratumoral (endoscopic) SIL204 overcomes physical barrier of primary tumor Lipid conjugated siRNA targets high LDL receptor expressing tumors and micrometastases

Potentially the most advanced gene silencing oncology product in clinical development • Potential efficacy advantage from silencing KRAS upstream of inhibitors • Protential safety advantage with KRAS - specific targeting and absent RAS off - target binding • Targets both primary tumor and metastatic disease • Enhanced delivery into cancer cells • Better stability • Broad antitumor activity SIL204 Combines KRAS Silencing with Dual Delivery Designed to target both primary tumors and micrometastatic disease

11 0 0.2 0.4 0.6 0.8 1 control 5 nM 50 nM Normalized fold (2 - ∆∆Ct) mRNA **** **** 0 0.2 0.4 0.6 0.8 1 control 5nM 50nM KRAS/ GAPDH Normalized fold KRAS Protein SIL204 Silences KRAS RNA with Corresponding Reduced KRAS Protein Transfection with lipofectamine PK59 human tumor line G12D mutation Analysis at 72 hrs for mRNA and protein **** = p value ＜ 0.0001

SIL204 Highly Effective with Broad Inhibition Across Human KRAS Mutations at Sub - nanomolar Concentrations SIL 204 maintains and expands the silencing activity of first generation siG 12 DLoder 12 Model is a co - transfection setup where human KRAS is transfected in mouse Hepa1 - 6 cells with Dual - Glo reporter plasmids. KRAS G13D * KRAS Q61H * KRAS G12R KRAS G12C KRAS G12V KRAS G12D WT KRAS Negative siRNA Control Mutation 0.37 0.24 0.59 0.47 0.44 0.19 0.16 IC 50 (nM) 88 88 71 73 80 90 91 0 - 7 MAX Inhibition (%) IC 50 =half - maximal inhibitory concentration. *G13D and Q61H tested in separate studies from the G12 mutations and wild type (non - mutated). Negative siRNA control collected over various studies

SIL204 Inhibits Growth of Multiple Mutant KRAS+ Human Tumor Cell Lines SIL204 inhibits proliferation across four human cancer cell lines ( CTG assay) 13 Broad antitumor activity at clinically achievable concentrations CTG= CellTiter - Glo IC 90 (ng/mL) IC 90 ( nM ) IC 50 (ng/mL) Cell line KRAS mutation subtype 1 , 079 70 537 A427 (Lung) G12D 2 , 496 163 1,059 PK59 ( Panc ) G12D 852 56 445 GP2D ( C olon) G12D 1 , 907 124 476 HS766T ( Panc ) Q61H 1,583 103 613 AVG Results confirm and extend prior pan - KRAS silencing observed in transfected hepa cells Average growth inhibition across tumor lines: IC 50 613 ng/mL, 40 nM IC 90 1,583 ng/mL, 103 nM

In Silico Analysis Supports SIL204 Specificity for KRAS Predicted binding to KRAS G12V with low predicted off - target activity against HRAS/NRAS • SIL204 binding to KRAS G12V strong ( - 31.8 kcal/mole) • No Off - Target Active Anti - sense Binding indicating l ow risk for side effects. • No effect on regulatory RNAs Conclusions • SIL - 204 silences the intended target KRAS mutations, with low off - target risk for potential improved safety profile over existing RAS inhibitors • HRAS and NRAS very unlikely affected, continuous endogenous RAS activity Analysis conducted by Dr. James McSwiggen, McSwiggen Biotech Consulting LLC 14 14

Intratumor Administered SIL 204 Inhibited Human Pancreatic Cancer Xenograft Growth in Mice 15 SIL204 significantly reduced tumor volume and growth while increasing tumor necrosis (cell death) *p<0.05 ; ***p<0.0005 s.c. . = subcutaneous. Day 1: Capan - 1 (KRAS G12V) luciferase cells were xenografted to mice ( s.c. ) concurrently with SIL204 formulated in extended - release microparticles Days 3 - 15: mice were evaluated for bioluminescence to evaluate relative tumor cell counts Day 15: tumors were removed, area determined and analyzed by histology for % necrosis from tumor center slice % Necrosis 0 5 10 15 20 25 30 35 40 45 50 Vehicle SIL-204 5.00E+05 1.50E+06 2.50E+06 3.50E+06 4.50E+06 5.50E+06 3 8 13 18 Time (Days) Vehicle SIL-204 5.5 4.5 3.5 2.5 1.5 0.5 Bioluminescence (10 6 ) Tumor area (mm 2 ) 30 35 40 45 50 55 60 Vehicle SIL-204 % Area Necrosis at Day 15 Average Tumor Area at Day 15 Average Tumor Cell Number

SIL204 Enhancements Result in Improved Stability 16 SIL 204 maintains therapeutic levels in target tissues for > 28 days PK profiles of SIL204 after a single s.c. administration were determined in Sprague Dawley rats using a LC - MS/MS analytical method, in the plasma and after collection f rom kidney, liver, and skin. IC90 is the concentration for 90% inhibition of tumor cell growth, IC50 is the concentration to achieve 50% inhibition 1 10 100 1,000 10,000 100,000 1,000,000 10,000,000 0 7 14 21 28 35 42 49 56 SIL 204 Concentration (ng/mL) or (ng/g) Time ( Day ) Plasma Kidney(left) Liver Skin IC 90 IC 50 Potential for monthly dosing to control micrometastatic disease

Systemic Administration of siRNA Strongly Supported by Preclinical Data 17 Subcutaneous SIL204 proved effective in mouse metastatic pancreatic orthotopic models Human tumor cell line Panc - 1 harboring KRAS G 12 D mutation Animal model represents human equivalent dose (HED) of SIL - 204 SC SIL204 ablated xenograft tumor 0 7 14 -20 0 20 40 60 80 100 120 140 Days following SIL204 subcutaneous injection Negative Control SIL204- High Dose Control High dose SIL 204 0.00E+00 2.00E+05 4.00E+05 6.00E+05 intestine liver stomach spleen Bioluminescence Bioluminescence Change (%) Bioluminescent imaging of metastatic organs

SIL204’s Anti - Tumor Activity Synergistic with Pancreatic Cancer Chemotherapy * p<0.05, ***p<0.0005 Human pancreatic cell line Panc - 1 (G12D) 18 15 25 35 45 Untreated FOLFIRI 50µM FOLFIRI 50µM+SIL-204 Cell Confluence Panc 1 cell confluence after 67 hrs *

Toxicology • Extended single - dose GLP toxicity studies completed in 2 relevant species, aligned with ICH S9 guidance for oncology and confirmed by regulatory agency for initiation of Phase 2/3 clinical trial • Established safety margins of up to 11 - fold over the clinical starting dose. • SIL204 was well - tolerated in both species with no test article - related organ toxicity or mortality observed. • Adverse findings limited to non - adverse changes at local injection site, fully resolved at 1 month. • No evidence of complement activation or immunotoxicity . • Toxicology package for marketing approval planned for H2, 2026 Favorable Tolerability with No Systemic Toxicity or Organ Damage

SIL 204 Phase 2 / 3 Clinical Trial Initiated July 2026 Dose escalation in LAPC subjects treated with SIL 204 - IR at 3 dose levels + SoC chemotherapy ( n ≈ 15 – 18 ) Primary Objective: Identify Phase 2 expansion doses Randomized, 3 arm study comparing SIL 204 - IR at 2 dose levels + SoC chemo vs SoC chemo alone (n ≈ 166 ) Primary Objective: Identify Phase 3 confirmatory dose Randomized, 2 - arm study comparing SIL 204 - IR + SoC chemo vs SoC chemo alone (n ≈ 222 ) Primary Objective: Efficacy/Safety for marketing approval Segment 1 : Phase 2 / 3 safety run - in initiation mid - 2026 Expected completion Q 2 2027 Segment 2 : Phase 2 expansion Initiation Q 3 2027 Segment 3: Phase 3 confirmatory Initiation Q3 2030 SIL204 administered intratumorally and systemically as an integrated treatment regimen (IR) Primary endpoint: Overall survival (OS) Secondary endpoints: ct DNA biomarker data (expected early Q4, 2026), Progression - free survival (PFS), overall response rate (ORR) 2028 Trial Interim results Sample size adjustment

Strategic Collaboration for SIL 204 GMP Clinical Supply with Leading European Manufacturers Collaboration to leverage Catalent and Axolabs ’ experience in formulation development and manufacturing biologicals to further enhance SIL 204 's therapeutic potential through improved stability, bioavailability, and delivery precision. Catalent Limoges Facility A European Center of Excellence for clinical biologics formulation development and drug manufacture Axolabs Facility Leveraging expertise and large - scale nucleic acid production

Silexion advancing SIL 204 Phase 2 / 3 Development Plan GMP clinical supply for Ph 2 / 3 safety run - in manufactured Toxicology complete for Ph 2 / 3 safety run - in Positive scientific advice from the EMA received I nitiation of Ph 2 / 3 approved by Israel ’ s MoH and Germany ’ s BfArM Initiated Ph 2 / 3 safety run - in Early human data regarding SIL - 204 expected Q 4 , 2026 IND application Q 1 , 2027 Expansion Phase 2 / 3 to USA and EU countries submission and initiation Q 1 , 2027 Segment 2 : Phase 2 expansion Q 1 , 2027

SIL 204 First in class siRNA targeting KRAS - driven cancers • SIL 204 Phase 2 / 3 in locally advanced pancreatic cancer received regulatory approval in Israel and Germany, initiated clinical trial July 2026 ; pre - IND meeting with FDA expected early 2027 • Isoform - selective, pan KRAS silencer, stable siRNA with targeted delivery system • Preclinical proof of concept in additional KRAS - driven cancers including CRC First generation product showed KRAS silencing potential but highlighted delivery limitation Second generation product (SIL204) designed for enhanced cellular delivery, better stability, and broader antitumor activity D ual - delivery strategy targets both primary lesion and metastases

Thank You Nasdaq: SLXN Ilan Hadar Chairman & Chief Executive Officer email: i hadar@silexion.com Dr. Mitchell Shirvan Chief Scientific and Development Officer email: m shirvan@silexion.com Mirit Horenshtein Hadar, CPA Chief Financial Officer email: mirit@silexion.com

Intellectual Property Protection Exclusivity can be extended under country - specific regulatory - based extension rules. Term Submissions Expected protection until 2043 plus estimated extension to 2048 Entered national Phase world wide, SIL - 204 as a composition and for use in treatment of pancreatic and other cancers (following successful USPTO review of PCT) U.S. Patent Application No. 19/443,507 CIP of U.S. Patent Application No. 19/138,670 Pending US/EU, expected term till 2040 plus extension siRNA against KRAS G12x for regional perineural invasion or pain associated with a solid tumor U.S. Patent Application No. 19/443,507

World - Renowned Expert Scientific Advisory Board Eileen M. O'Reilly, MD Memorial Sloan Kettering, NY, NY Winthrop Rockefeller Endowed Chair of Medical Oncology; Co - Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research; Section Head, Hepatopancreatobi Hana Algul , MD Technical University of Munich, Germany chair for tumor metabolism; Director of the Comprehensive Cancer Center Munich, Germany at the Klinikum rechts der Isar, and Mildred - Scheel - professor and Milind Javle , MD The University of Texas & MD Anderson Cancer Center, Houston, TX Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine Philip A. Philip, MD Henry Ford Health, Detroit, MI Director, Gastrointestinal Oncology; Co - Director, Pancreatic Cancer Center; Medical Director, Research and Clinical Care Integration, Henry Ford Cancer Institute Talia Golan, MD Sheba Tel Hashomer Hospital, Israel Head, Sheba Pancreatic Cancer Center - SPCC Matthew Katz, MD The University of Texas & MD Anderson Cancer Center, Houston, TX Department Chair, Department of Surgical Oncology, Division of Surgery and Professor. Andrew M. Lowy, MD UC San Diego, San Diego, CA Chief, Division of Surgical Oncology; Professor of Surgery Mark A. Schattner , MD Memorial Sloan Kettering, NY, NY Chief, Gastroenterology, Hepatology and Nutrition Service 26 Thomas Seufferlein , MD University Hospital Ulm, German y Director of Internal Medicine University Hospital Ulm, President German Cancer Society

Highly Experienced Leadership Team Ilan Hadar , MBA Chairman and Chief Executive Officer Over 25 years of multinational executive managerial and corporate experience with pharmaceutical and high - tech companies . CEO Pain R eform ( “ PRFX ” ), CFO Foamix Pharmaceuticals Inc . (Currently “ VYNE ” ) Mitchell Shirvan, PhD, MBA Chief Scientific and Development Officer Over 30 years of experience in R&D, innovation and discovery in biotech companies . CEO Macrocure Ltd . , Sr . V . P . R&D Foamix Pharmaceuticals Inc . (Currently “ VYNE ” ) , Sr . Director Strategic Business Planning Teva Pharmaceuticals Industries Inc . Mirit Horenshtein Hadar, CPA Chief Financial Officer Over 15 years of corporate finance experience in senior financial positions of public companies and privately held companies, in the pharmaceutical and high - tech industries . CFO Gouzy Israel (“GAUZ”) . V . P . Finance Foamix Pharmaceuticals Inc . (Currently “VYNE”) 27

GRAPHIC

Filename: image_001.jpg · Sequence: 7

Binary file (99012 bytes)

Download image_001.jpg

GRAPHIC

Filename: image_002.jpg · Sequence: 8

Binary file (245904 bytes)

Download image_002.jpg

GRAPHIC

Filename: image_003.jpg · Sequence: 9

Binary file (153071 bytes)

Download image_003.jpg

GRAPHIC

Filename: image_004.jpg · Sequence: 10

Binary file (123199 bytes)

Download image_004.jpg

GRAPHIC

Filename: image_005.jpg · Sequence: 11

Binary file (135676 bytes)

Download image_005.jpg

GRAPHIC

Filename: image_006.jpg · Sequence: 12

Binary file (99696 bytes)

Download image_006.jpg

GRAPHIC

Filename: image_007.jpg · Sequence: 13

Binary file (131627 bytes)

Download image_007.jpg

GRAPHIC

Filename: image_008.jpg · Sequence: 14

Binary file (168914 bytes)

Download image_008.jpg

GRAPHIC

Filename: image_009.jpg · Sequence: 15

Binary file (122362 bytes)

Download image_009.jpg

GRAPHIC

Filename: image_010.jpg · Sequence: 16

Binary file (113007 bytes)

Download image_010.jpg

GRAPHIC

Filename: image_011.jpg · Sequence: 17

Binary file (88105 bytes)

Download image_011.jpg

GRAPHIC

Filename: image_012.jpg · Sequence: 18

Binary file (120843 bytes)

Download image_012.jpg

GRAPHIC

Filename: image_013.jpg · Sequence: 19

Binary file (115887 bytes)

Download image_013.jpg

GRAPHIC

Filename: image_014.jpg · Sequence: 20

Binary file (123878 bytes)

Download image_014.jpg

GRAPHIC

Filename: image_015.jpg · Sequence: 21

Binary file (134148 bytes)

Download image_015.jpg

GRAPHIC

Filename: image_016.jpg · Sequence: 22

Binary file (114755 bytes)

Download image_016.jpg

GRAPHIC

Filename: image_017.jpg · Sequence: 23

Binary file (115616 bytes)

Download image_017.jpg

GRAPHIC

Filename: image_018.jpg · Sequence: 24

Binary file (58105 bytes)

Download image_018.jpg

GRAPHIC

Filename: image_019.jpg · Sequence: 25

Binary file (114862 bytes)

Download image_019.jpg

GRAPHIC

Filename: image_020.jpg · Sequence: 26

Binary file (169602 bytes)

Download image_020.jpg

GRAPHIC

Filename: image_021.jpg · Sequence: 27

Binary file (201681 bytes)

Download image_021.jpg

GRAPHIC

Filename: image_022.jpg · Sequence: 28

Binary file (102611 bytes)

Download image_022.jpg

GRAPHIC

Filename: image_023.jpg · Sequence: 29

Binary file (135365 bytes)

Download image_023.jpg

GRAPHIC

Filename: image_024.jpg · Sequence: 30

Binary file (95839 bytes)

Download image_024.jpg

GRAPHIC

Filename: image_025.jpg · Sequence: 31

Binary file (102958 bytes)

Download image_025.jpg

GRAPHIC

Filename: image_026.jpg · Sequence: 32

Binary file (154560 bytes)

Download image_026.jpg

GRAPHIC

Filename: image_027.jpg · Sequence: 33

Binary file (134215 bytes)

Download image_027.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 35

v3.26.1

Cover

Aug. 10, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 10, 2026

Entity File Number

001-42253

Entity Registrant Name

Silexion Therapeutics

Corp

Entity Central Index Key

0002022416

Entity Tax Identification Number

00-0000000

Entity Incorporation, State or Country Code

Entity Address, Address Line One

12 Abba Hillel Road

Entity Address, City or Town

Ramat-Gan

Entity Address, Country

Entity Address, Postal Zip Code

5250606

City Area Code

+972

Local Phone Number

3-756-4999

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock [Member]

Title of 12(b) Security

Ordinary Shares, par value $0.135 per share

Trading Symbol

SLXN

Security Exchange Name

NASDAQ

Warrants Exercisable For Ordinary Shares [Member]

Title of 12(b) Security

Warrants exercisable for Ordinary Shares at an exercise price of $15,525.00 per share

Trading Symbol

SLXNW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=SLXN_WarrantsExercisableForOrdinarySharesMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: